Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,489
datasets available to search
ShareScore release 0.9.0
Dataset results
2,489 results for “Sars-CoV-2”
Fig. 1 in Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
Fig. 1. Functions of SARS-CoV-2 PLpro and benefits by targeting PLpro. (A) PLpro proteolyzes viral polyprotein at the LXGG site to generate mature nsp1, nsp2 and nsp3. (B) PLpro removes ISG15 and ubiquitin modifiers from host proteins to evade innate antiviral immunity.
Fig. 4 in Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
Fig. 4. Possible interactions of biflavones 1, 7, and 6 with PLpro. (A–C) Binding interactions represented in the Corey-Pauling-Koltun (CPK) model. (D–F) Binding interactions represented in the ball-stick model. The interacting amino acid residues are labelled in black. The hydrogen bonds are indicated by yellow dashed lines with the distances given in Å. The P3 and P4 regions of the substrate binding pocket of PLpro are indicated by corresponding labels. (G–I) 2D diagram of the binding interactions. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Multimodal immune profiling of SARS-CoV-2 in Uganda – soluble immune mediators
<p>Little is known about the pathobiology of SARS-CoV-2 infection in sub-Saharan Africa, where severe COVID-19 fatality rates are among the highest in the world and the immunological landscape is unique. In a prospective cohort study of 306 adults encompassing the entire clinical spectrum of SARS-CoV-2 infection in Uganda, we integrated profiling of the peripheral blood proteome and transcriptome to dissect the immunopathology of COVID-19 across multiple phases of the pandemic. Beyond the prognostic importance of myeloid cell-driven immune activation and lymphopenia, we show that multifaceted impairment of host protein synthesis and extensive redox imbalance define core biological signatures of severe COVID-19, with central roles for IL-7, IL-15, and lymphotoxin-α in COVID-19 respiratory failure. While prognostic signatures were generally consistent in SARS-CoV-2/HIV-coinfection, type I interferon responses uniquely scaled with COVID-19 severity in persons living with HIV. Throughout the pandemic, COVID-19 severity peaked during phases dominated by A.23/A.23.1 and Delta B.1.617.2/AY variants. Independent of clinical severity, Delta phase COVID-19 was distinguished by exaggerated pro-inflammatory myeloid cell and inflammasome activation, NK and CD8+ T-cell depletion, and impaired host protein synthesis. Combining these analyses with a contemporary Ugandan cohort of adults hospitalized with influenza and other severe respiratory infections, we found activation of epidermal and platelet-derived growth factor pathways to be distinct features of COVID-19, deepening translational understanding of mechanisms potentially underlying SARS-CoV-2-associated pulmonary fibrosis. Collectively, our findings provide biological rationale for use of broad and targeted immunotherapies for severe COVID-19 in sub-Saharan Africa, illustrate the relevance of local viral and host factors to SARS-CoV-2 immunopathology, and highlight underemphasized yet therapeutically exploitable immune pathways driving COVID-19 severity.</p>
Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution
<p>Supplementary figures and additional graphs described in "Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution". (version 2)</p>
Source Code: Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution
Open the record for dataset details and reuse information.
A Open One-Step RT-qPCR for SARS-CoV-2 detection
<p>Sequences of the plasmids needed to purify the required enzymes for a standardized One-Step open RT-qPCR protocol to detect SARS-CoV-2 RNA in clinical samples. Supplementary Information</p>
Assessment of the Humoral Immune Response to the SARS-CoV-2 Spike Protein Receptor Binding Motif
<p><strong>Figure S1.</strong> Purification of human antibodies against the RBM region of the SARS-CoV-2 spike protein using a recombinant RBM Sepharose 4B affinity column (3 x 1 cm, inner diameter) (A) and SDS-PAGE (10%) analysis of the eluate (1) alongside a standard low molecular weight marker (Sigma Chemical Co, Saint Louis, Mo, U.S.A.) stained with Coomassie Blue. <strong>Table S1</strong>: Microscale thermophoresis (MST) traces of anti-RBM antibodies binding to different concentrations of S1WT (red) and S2WT (green) peptides by MST. Relative fluorescence (RF) between the bound and unbound state was determined over a time of 21s with 20s MST-on time for evaluation. The blue bar indicates the ΔRF before the temperature gradient was applied, whereas the red bar shows the ΔRF during the thermophoresis. For interaction experi ments, the amount of NT.647-labeled antibodies was kept constant, while the concentration of unlabeled peptides varied from 0.5 µg/mL–0.12 ng/mL. The assay was performed in PBS containing 0.05% Tween 20 and after a short incubation period, the samples were analyzed in standard glass MST NT.115 capillaries. <strong>Table S2:</strong> One-dose regime AstraZeneca-Oxford vaccinated serum information. <strong>Table S3</strong>: Heterologous booster dose vaccinated serum information.</p>
Late Respiratory Consequences of SARS-CoV-2 Pneumonia
ClinicalTrials.gov study NCT05812196. IPD Sharing: NO. Countries: 1. Publications: 1.
Sequelae of Sars-CoV-2 Infections
ClinicalTrials.gov study NCT04442789. IPD Sharing: NO. Countries: 1. Publications: 11.
Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)
ClinicalTrials.gov study NCT04351646. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
ClinicalTrials.gov study NCT04325646. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study
ClinicalTrials.gov study NCT04340466. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults
ClinicalTrials.gov study NCT04818281. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subje
ClinicalTrials.gov study NCT04563702. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination
ClinicalTrials.gov study NCT05009134. IPD Sharing: NO. Countries: 1. Publications: 2.
Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 1)
ClinicalTrials.gov study NCT05194033. IPD Sharing: UNDECIDED. Countries: 1. Publications: 25.
Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy
ClinicalTrials.gov study NCT06968897. IPD Sharing: NO. Countries: 1. Publications: 1.
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
ClinicalTrials.gov study NCT04414631. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Public Perception and Policy for SARS-CoV-2 Whole Genome Sequencing and Genomics for All
ClinicalTrials.gov study NCT06441981. IPD Sharing: NO. Countries: 1. Publications: 2.
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
ClinicalTrials.gov study NCT05897541. IPD Sharing: NO. Countries: 5. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.